-
Specialty pharmacy utilization continues to rise, Walgreens executive says
MIAMI — The utilization of specialty pharmacy is projected to steadily increase, Walgreens VP clinical affairs David Lorber told attendees Tuesday at the Pinsonault Associates Managed Markets Summit, which accentuates a need to augment patient compliance and help payers get a handle on what have become rapidly shifting economics.
-
Sylatron OKed as add-on melanoma treatment
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a treatment made by Merck for treating skin cancer, Merck said Monday.
Merck announced the approval of Sylatron (peginterferon alfa-2b) as an add-on treatment for treating melanoma with microscopic of gross nodal involvement within 84 days of surgery.